MDPI and ACS Style
Kawakami, H.; Hironaka, S.; Esaki, T.; Chayama, K.; Tsuda, M.; Sugimoto, N.; Kadowaki, S.; Makiyama, A.; Machida, N.; Hirano, H.;
et al. An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7). Cancers 2021, 13, 805.
https://doi.org/10.3390/cancers13040805
AMA Style
Kawakami H, Hironaka S, Esaki T, Chayama K, Tsuda M, Sugimoto N, Kadowaki S, Makiyama A, Machida N, Hirano H,
et al. An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7). Cancers. 2021; 13(4):805.
https://doi.org/10.3390/cancers13040805
Chicago/Turabian Style
Kawakami, Hisato, Shuichi Hironaka, Taito Esaki, Kazuaki Chayama, Masahiro Tsuda, Naotoshi Sugimoto, Shigenori Kadowaki, Akitaka Makiyama, Nozomu Machida, Hidekazu Hirano,
and et al. 2021. "An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)" Cancers 13, no. 4: 805.
https://doi.org/10.3390/cancers13040805